drugset / Trial / NCT05136365
A Study of Xiongdan Wan Treating Depression
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, open-label study to evaluate the safety and efficacy of Xiongdan Wan monotherapy in patients with Major Depressive Disorder(MDD), conducted in Shang Hai Mental Health Center. Following a screening period, subjects who meet the entry criteria will be treated with 450mg Xiongdan Wan pills three times daily for 8 weeks.
Timeline
- Start
- 2021-12-28
- Primary completion
- 2022-08-30
- Completion
- 2022-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Xiongdan Wan | Unknown | 450 mg | Oral |